NCT00061711

Brief Summary

This randomized, controlled trial will evaluate the efficacy and safety of three alternative approaches utilizing phytoestrogens to treat hot flashes and night sweats in peri- and post-menopausal women. The treatments were chosen because of the scientific evidence supporting a possible benefit, the availability of products with adequate quality control, and their frequency of use in naturopathic medicine. RECRUITMENT FOR THIS STUDY SHOULD END BY AUGUST 1, 2003.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
355

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2000

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2000

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

June 3, 2003

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 4, 2003

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2005

Completed
Last Updated

December 11, 2009

Status Verified

December 1, 2009

Enrollment Period

5.4 years

First QC Date

June 3, 2003

Last Update Submit

December 9, 2009

Conditions

Interventions

Eligibility Criteria

Age45 Years - 55 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Female, aged 45-55.
  • Peri- or post-menopausal, defined as having no menstrual periods for at least 12 months prior to study entry, or skipping at least one menstrual period in the 12 months prior to study entry. Peri- or post-menopausal status will be determined for candidates who have had the uterus removed by an assessment of blood follicle stimulating hormone (FSH). Women with an FSH level higher than 20 mlU/mL will be eligible for the study.
  • Experiencing an average of 2 or more hot flashes or night sweats per day, of which 6 or more must be of moderate or greater intensity over two weeks.
  • Normal thyroid stimulating hormone (TSH) measured prior to study entry, defined as 0.4 - 5.0 ulU/ML.
  • Proof of negative mammogram within two years prior to randomization. Subjects may provide copies of the mammogram results or a letter from their primary care provider.
  • Must provide informed consent.
  • Not at high risk for medical complications that might affect the subject's ability to complete the trial without a serious co-morbid event, based on medical history, physical examination and laboratory screening evaluation.

You may not qualify if:

  • Mentally or legally incapacitated such that informed consent cannot be obtained.
  • Use of hormone replacement therapy or oral contraceptives within the past three months.
  • Use of alternative or complementary medicines or herbs for menopausal symptoms within the past one month.
  • History of any illness or having significant abnormalities on prestudy clinical or laboratory evaluation such that in the opinion of the investigator participating in this study might pose an unacceptable risk to the subject.
  • The subject has a medical history of any of the following contraindications to HRT: breast cancer, uterine cancer, endometrial hyperplasia, angina treated with medication, myocardial infarction, revascularization surgery, coronary angioplasty, stroke, blood clots, active chronic liver disease, or nephrotic syndrome.
  • Bone mineral density of the hip or spine more than two standard deviations below the age-specific mean.
  • bilateral oophorectomy.
  • Current use of any of the following medications: tamoxifen, raloxifene, bisphosphonates, cholesterol-lowering medications, prescription blood-thinners, or oral steroids.
  • Pregnant or planning to become pregnant.
  • Baseline blood pressure greater than 160/95 mm Hg.
  • Alergy to soybeans or soy protein.
  • Unable to swallow pills.
  • Current participation in another investigational drug trial.
  • Intention to move within the next 12 months rendering follow-up per the protocol impossible.
  • Noncompliance in the procedures involved with the screening visit or run-in trial. To be compliant, subjects must take at least 80% of the run-in medication (can miss 2-1/2 days) and complete at least 80% of the baseline symptom diaries (can miss 3 days of the hot flash and night sweats diaries, must complete all Wiklund checklists).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Health Studies Research Clinic

Seattle, Washington, 98101, United States

Location

Related Publications (5)

  • Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol. 2002 Jul;100(1):18-25. doi: 10.1016/s0029-7844(02)02005-7.

    PMID: 12100799BACKGROUND
  • Phelan EA, Buist DS, Anderson LA, Newton KM, Delaney KM, LaCroix AZ. Understanding attitudes of older women toward hormone replacement therapy. Prev Med. 2001 Jan;32(1):49-56. doi: 10.1006/pmed.2000.0768.

    PMID: 11162326BACKGROUND
  • Newton KM, LaCroix AZ, Leveille SG, Rutter C, Keenan NL, Anderson LA. Women's beliefs and decisions about hormone replacement therapy. J Womens Health. 1997 Aug;6(4):459-65. doi: 10.1089/jwh.1997.6.459.

    PMID: 9279834BACKGROUND
  • Newton KM, LaCroix AZ, Buist DS, Keenan NL. The use of alternative and complementary medicine by women enrolled in an HMO setting. Menopause, 1998, 5:244.

    BACKGROUND
  • Newton KM, Reed SD, Grothaus L, Ehrlich K, Guiltinan J, Ludman E, Lacroix AZ. The Herbal Alternatives for Menopause (HALT) Study: background and study design. Maturitas. 2005 Oct 16;52(2):134-46. doi: 10.1016/j.maturitas.2005.01.007.

MeSH Terms

Conditions

Hot Flashes

Interventions

Hormone Replacement Therapyblack cohosh root extract

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Drug TherapyTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

June 3, 2003

First Posted

June 4, 2003

Study Start

July 1, 2000

Primary Completion

December 1, 2005

Study Completion

December 1, 2005

Last Updated

December 11, 2009

Record last verified: 2009-12

Locations